Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | PTGFR | P43088 | 1/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
| ▸ | PTGIR | P43119 | 1/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.40 |
| ▸ | ITGAL | P20701 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207341 | 1.00 | HPGD (0.49) | HPGDNPSR1L3MBTL1TBXA2RPTGFR | |
| SCHEMBL3204053 | 0.82 | HPGD (0.52) | HPGDNPSR1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL3198916 | 0.81 | TBXA2R (0.49) | HPGDNPSR1L3MBTL1TBXA2RPTGFR | |
| SCHEMBL3198904 | 0.81 | TBXA2R (0.49) | HPGDNPSR1L3MBTL1TBXA2RPTGFR | |
| SCHEMBL6185207 | 0.81 | TBXA2R (0.46) | HPGDNPSR1L3MBTL1TBXA2RPTGFR | |
| SCHEMBL6185200 | 0.81 | TBXA2R (0.46) | HPGDNPSR1L3MBTL1TBXA2RPTGFR | |
| SCHEMBL6180604 | 0.79 | TBXA2R (0.45) | HPGDNPSR1L3MBTL1TBXA2RPTGFR | |
| SCHEMBL6180601 | 0.79 | TBXA2R (0.45) | HPGDNPSR1L3MBTL1TBXA2RPTGFR | |
| SCHEMBL3202438 | 0.78 | PPARG (0.62) | HPGDNPSR1L3MBTL1PTGER3 | |
| SCHEMBL3202431 | 0.78 | PPARG (0.62) | HPGDNPSR1L3MBTL1PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| EP-1912645-A2 | THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| WO-2007018314-A2 | THERAPEUTIC AGENT FOR DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | HPGD 1030/4885NPSR1 1882/4885L3MBTL1 2201/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | HPGD 811/4885NPSR1 1130/4885L3MBTL1 2043/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | HPGD 1030/4885NPSR1 1882/4885L3MBTL1 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.